our story, our mission
our founder, Professor Yoram Palti
We are striving to extend survival in some of the most aggressive forms of cancer.
In 2000, Yoram Palti, our founder and professor emeritus of physiology and biophysics at the Technion — Israel Institute of Technology, sought to leverage his expertise in biophysics to develop a new way to treat solid tumor cancers that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies.
He set up a laboratory in his basement to explore the potential of electric fields as a treatment for solid tumors.
Professor Palti founded Novocure to provide patients with a new cancer treatment based on his hypothesis, since proven, that alternating electric fields, when applied at specific frequencies, can disrupt cancer cell division. This innovative treatment, Tumor Treating Fields, is a completely different approach to cancer therapy.
“Nobody understood what I was doing,” Professor Palti said of his early development of Tumor Treating Fields.
Palti’s initial research from his basement laboratory evolved to become Novocure – an international oncology company with more than 1,300 employees and operations in North America, Europe, the Middle East and Asia.
Our company began with a patient-forward approach that continues to drive our mission today. With more than 20 years of research and many significant milestones, we believe we are only beginning.
from day one forward
Aspiring to make a difference in cancer, from day one
our mission:
Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer by developing and commercializing our innovative therapy.
our vision:
Patient-forward: aspiring to make a difference in cancer
Our history
Novocure was founded in 2000 by Prof. Yoram Palti, who discovered the effects of TTFields on cancer cells. Today, we are an international oncology company.
our values
leadership at Novocure
Our leaders have extensive experience across oncology, biotechnology and medical device industries.